INTRODUCTION
============

With widespread use of endovascular interventions for patients with leg artery occlusive disease, lower extremity arterial bypasses (LEAB) are decreasingly being used. However, LEAB is still the most durable treatment option.

The superiority of autogenous vein conduits to prosthetic grafts is well accepted in LEAB, particularly in distal leg bypass. It has been reported that ipsilateral great saphenous vein (GSV) is regarded as the first choice conduit for lower limb bypass \[[@b1-vsi-32-160]--[@b6-vsi-32-160]\]. However up to 20%--45% of patients requiring bypass surgery do not have an available GSV in both extremities due to inadequate size, length, or prior usage \[[@b7-vsi-32-160],[@b8-vsi-32-160]\]. The alternative autogenous conduits include the small saphenous vein (SSV), basilic or cephalic arm veins, inferior epigastric artery and composite vein \[[@b8-vsi-32-160],[@b9-vsi-32-160]\]. The objective of this study was to present the long-term results of arm vein graft in LEAB.

MATERIALS AND METHODS
=====================

1). Study design, patient, and data collection
----------------------------------------------

This retrospective study included twenty-eight patients who underwent infrainguinal LEAB with autogenous arm vein graft due to the absence of adequate saphenous vein graft from January 2003 to December 2015 at Samsung Medical Center, Seoul, Korea. This study was approved by the Institutional Review Board of Samsung Medical Center (No. smc-2016-12-094) and the patients' consents were waived.

Arm vein was used for 12 initial procedures and for 16 revision procedures of previous bypass grafts and/or endovascular procedures. Assessment of vein availability and its quality was performed by vein mapping with preoperative routine duplex ultrasonography. The saphenous vein was considered unusable if it was too small (\<2 mm) or occluded due to thrombus on duplex ultrasonography. Therefore, if preoperative scan showed that bilateral saphenous veins were not suitable for bypass in all patients, arm veins were scanned for bypass conduit with duplex ultrasonography. Arm veins were regarded as suitable vein grafts when the measured diameters were at least 2 mm. Vein mapping was performed by registered vascular technologists marking the courses of cephalic and/or basilic veins from the wrist to the axillary fossa.

All LEAB patients with arm vein grafts underwent duplex ultrasonography to evaluate graft patency at postoperative 1, 6, 12 months and every 6 to 12 months thereafter.

This study used definitions and classification of all criteria as those recommended by the Ad Hoc Committee on Reporting Standards appointed by the Society of Vascular Surgery and the North American chapter of the International Society of Cardiovascular Surgery \[[@b10-vsi-32-160]\].

2). Statistical analysis
------------------------

Primary, primary-assisted, secondary patency and limb salvage rates were calculated using the Kaplan-Meier method. Log-rank test was used to examine differences between each group. Student's t-test was used to compare continuous variables. Statistical analysis was performed with IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). P-values of \<0.05 were considered as statistically significant.

RESULTS
=======

1). Patient characteristics
---------------------------

Mean age of patients was 60.4 years and 92.9% of patients were male. Twenty cases (71.4%) of arm vein bypass were performed for limb salvage of the patients with critical limb ischemia (Rutherford category 4 and 5) and 8 (28.6%) for the patients with severe claudication (Rutherford category 3). The reasons for absence of GSV are listed as follows: 14 patients (50.0%) had undergone previous bypass procedures, 12 patients (42.9%) had inadequate GSV size or length and 2 patients (7.1%) had thrombus in their GSVs ([Table 1](#t1-vsi-32-160){ref-type="table"}).

The bypass grafts were composed of single arm vein segments in 17 cases (60.7%) and composite veins in 11 cases (39.3%) ([Table 2](#t2-vsi-32-160){ref-type="table"}). The most common inflow artery was the common femoral artery (11 cases, 39.3%) and most common outflow arteries were the anterior tibial and posterior tibial arteries (8 cases each, 28.6%) ([Table 3](#t3-vsi-32-160){ref-type="table"}).

2). Morbidity and mortality
---------------------------

The overall perioperative morbidity was reported in 4 patients (14.3%). It included acute myocardial infarction (n=1, 3.6%), stroke (n=2, 7.1%), and postoperative bleeding (n=1, 3.6%), while no morbidity was associated with the arm vein harvest procedure in our study. The 30-day mortality rate was 0%. During the mean follow-up period of 41.5±46.9 month (range, 1--138 months), 3 patients (10.7%) died from combined medical illness of cerebral hemorrhage, gastrointestinal bleeding, and aspiration pneumonia.

3). Graft patency and limb salvage
----------------------------------

The 1-year primary, assisted-primary and secondary patency rates were 66.5%±10.5%, 66.5%±10.5% and 70.8%±10.2%, respectively. Five-year primary, assisted-primary and secondary patency rates were 60.9%±11.0%, 66.5%±10.5% and 70.8%±10.2%, respectively ([Fig. 1](#f1-vsi-32-160){ref-type="fig"}). There was one limb amputation after bypass during the follow-up and 5-year limb-salvage rate was 94.4%±5.4%.

There was no significant difference in graft patency and limb salvage rate between single arm vein segment grafts and composite arm vein grafts. Five-year secondary patency of single arm vein segment graft and composite vein graft were 69.4%±12.1% and 71.4%±17.1% (P=0.78), respectively ([Fig. 2](#f2-vsi-32-160){ref-type="fig"}).

DISCUSSION
==========

The first study of lower limb bypass with arm vein conduit was reported in 1969 \[[@b11-vsi-32-160]\]. After that, several studies from the past decade have introduced good long term patency rates and limb salvage rates in lower limb bypass with arm vein conduit \[[@b8-vsi-32-160],[@b12-vsi-32-160]--[@b16-vsi-32-160]\]. Some groups have encouraged the use arm veins as the first alternative conduit when the ipsilateral GSV is absent due to the low morbidity of arm vein harvesting and for preservation of the contralateral GSV \[[@b8-vsi-32-160],[@b12-vsi-32-160],[@b13-vsi-32-160]\]. These studies showed that contralateral GSVs were subsequently used for either contralateral infrainguinal limb bypass (20%--23%) or coronary bypass (2%--3%).

Recent studies have reported that LEAB using arm vein conduits showed 3-year graft patency and limb salvage rates ranging from 40% to 73% and 63% to 92%, respectively \[[@b8-vsi-32-160],[@b12-vsi-32-160],[@b13-vsi-32-160],[@b16-vsi-32-160]\]. In our series, the overall 3-year patency and limb salvage rates were 60.9% and 94.4%, respectively. These results are comparable to other previous studies.

Despite the above evidence supporting the efficacy of arm vein grafts in patients with LEAB, it remains an infrequently used procedure because of concerns about the need to make composite veins in some patients to obtain adequate length. This has been considered a limitation to the use of arm vein graft as the venovenostomy has been shown to negatively affect the patency of these grafts \[[@b15-vsi-32-160]\]. However our study shows no negative effect on patency or limb salvage rate of composite vein grafts compared to single segment grafts.

We preferred basilic veins to cephalic veins as graft source. In our study, only 4 cephalic vein grafts were used for bypass. The cephalic vein is often inadequate for conduit due to prior puncture or trauma. Some authors suggest that the location of the basilic vein limits its utility as vascular access for hemodialysis and is thus less likely to be traumatized or can be avoided for venous puncture compared to the cephalic vein \[[@b17-vsi-32-160]\].

Arm veins or polytetrafluoroethylene (PTFE) grafts with adjunctive procedures could be considered as alternative bypass conduits when all saphenous veins are inadequate for LEAB bypass \[[@b18-vsi-32-160]\]. Previous studies showed that results from infrapopliteal bypass using prosthetic graft have been less satisfactory than those obtained with arm vein ([Table 4](#t4-vsi-32-160){ref-type="table"}) \[[@b8-vsi-32-160],[@b12-vsi-32-160],[@b16-vsi-32-160],[@b19-vsi-32-160]--[@b25-vsi-32-160]\]. In our institute, we prefer arm vein graft as a first choice of alternative graft in infrapopliteal bypass in the absence of adequate saphenous vein. In our study, subanalysis of infrapopliteal arm vein bypasses (23 cases) showed that 3-year primary patency, secondary patency, and limb salvage rates were 50.5%, 63.3%, 92.9%, respectively. By comparison, a meta-analysis of PTFE infrapopliteal bypass published in 2003 introduced 3-year primary patency, secondary patency, and limb salvage rates of 41%, 51%, and 66%, respectively \[[@b18-vsi-32-160]\]. The above results suggest that the arm vein is a favorable alternative conduit in infrapopliteal bypass when no saphenous veins are available.

The present study has several limitations. First, this study was a retrospective design and there could be some selection bias in the patients. Second, it was composed of small sample size, by which statistical power might be weak, although it is the largest case series reported in Korea. At last, there is no comparison group such as infrapopliteal bypass using prosthetic graft, so we presented some literature review and compared indirectly with several previous studies.

CONCLUSION
==========

Our results showed that the arm vein was a useful alternative conduit when great or SSV was not available during LEAB. In case of short length of vein, composite vein grafts are also a reliable conduit.

This article was presented at the 9th Japan-Korea joint meeting for vascular surgery, June 5, 2015, Yokohama, Japan.
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###### 

Patient characteristics (n=28)

  Characteristic                                           No. of grafts
  -------------------------------------------------------- --------------------
  Age (y)                                                  60.4±16.8 (20--82)
  Male                                                     26 (92.9)
  Etiology                                                 
    Atherosclerosis                                        19 (67.9)
    Non-atherosclerotic disease                            9 (32.1)
      Buerger's disease                                    5 (17.9)
      Chronic embolic occlusion                            1 (3.6)
      Others[^a^](#tfn2-vsi-32-160){ref-type="table-fn"}   3 (10.7)
  Indication                                               
    Rutherford category 3                                  8 (28.6)
    Rutherford category 4                                  8 (28.6)
    Rutherford category 5                                  12 (42.9)
    Non-healing ulcer                                      3 (10.7)
    Gangrene                                               9 (32.1)
  Prior treatment (n=16)                                   
    Leg bypass                                             14
    Endovascular intervention                              9
  Comorbidity                                              
    Diabetes mellitus                                      9 (32.1)
    Hypertension                                           13 (46.4)
    Ischemic heart disease                                 8 (28.6)
    Smoking                                                10 (35.7)
    Hyperlipidemia                                         9 (32.1)

Values are presented as mean±standard deviation (range), number (%), or number only.

Popliteal artery entrapment syndrome, iatrogenic femoral injury, popliteal artery aneurysm.

###### 

Graft source (n=28)

  Source of arm vein                                                      Grafts (n, %)
  ----------------------------------------------------------------------- ---------------
  Cephalic vein                                                           4 (14.3)
  Basilic vein                                                            13 (46.4)
  Composite vein                                                          11 (39.3)
  Basilic vein+cephalic vein composition                                  7 (25.0)
  Basilic vein+great saphenous vein or small saphenous vein composition   4 (14.3)

###### 

Anatomic configuration of bypass procedure

                                            Anastomosis level (n=28)          Grafts (n, %)
  ----------------------------------------- --------------------------------- ---------------
  Proximal                                  Common femoral artery             11 (39.3)
  SFA                                       10 (35.7)                         
  Popliteal artery                          5 (17.9)                          
  Other vein graft                          2 (7.1)                           
  Distal                                    Above knee popliteal artery/SFA   2 (7.1)
  Below knee popliteal artery               3 (10.7)                          
  Tibio-peroneal trunk                      1 (3.6)                           
  Anterior tibial artery                    8 (28.6)                          
  Posterior tibial artery                   8 (28.6)                          
  Peroneal artery                           4 (14.3)                          
  Dorsalis pedis artery                     1 (3.6)                           
  Infra-malleolar posterior tibial artery   1 (3.6)                           

SFA, superficial femoral artery.

###### 

Literature review of infrapopliteal bypass with arm vein or prosthetic graft

  Study                                                  Limbs no.   2--3 years patency rates (%)   2--3 years limb salvage rates (%)          
  ------------------------------------------------------ ----------- ------------------------------ ----------------------------------- ------ ------
  Veith et al., 1986 \[[@b20-vsi-32-160]\]               98                                         12                                         61
  Quiñones-Baldrich et al., 1992 \[[@b21-vsi-32-160]\]   28                                         22                                         37
  Parsons et al., 1996 \[[@b22-vsi-32-160]\]             66                                         39                                         71
  Jakobsen et al., 1998 \[[@b23-vsi-32-160]\]            39                                         50                                         75
  Wijesinghe et al., 1998 \[[@b24-vsi-32-160]\]          50                                         51                                         80
  Faries et al., 2000 \[[@b12-vsi-32-160]\]              55                                         41.1                                       63.2
  Arvela et al., 2010 \[[@b16-vsi-32-160]\]              160                                        10.4                                       57.1
  Calligaro et al., 1997 \[[@b19-vsi-32-160]\]           51                                         26                                         71
  Hölzenbein et al., 1996 \[[@b8-vsi-32-160]\]           250         51.9                                                               91.4   
  Faries et al., 2000 \[[@b12-vsi-32-160]\]              174         68.3                                                               81.4   
  Arvela et al., 2010 \[[@b16-vsi-32-160]\]              130         56.8                                                               75.0   
  Calligaro et al., 1997 \[[@b19-vsi-32-160]\]           28          46                                                                 76     
  Linni et al., 2015 \[[@b25-vsi-32-160]\]               32          52                                                                 87.5   
  This study                                             28          70.8                                                               94.4   
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